Francesco Novelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5391468/publications.pdf

Version: 2024-02-01

124 papers

6,527 citations

45 h-index 71685 **76** g-index

124 all docs

124 docs citations

times ranked

124

11071 citing authors

#	Article	IF	CITATIONS
1	Phosphoinositide Conversion Inactivates Râ€RAS and Drives Metastases in Breast Cancer. Advanced Science, 2022, 9, e2103249.	11.2	8
2	Discovery of Targets for Cancer Immunoprevention. Methods in Molecular Biology, 2022, 2435, 19-33.	0.9	1
3	Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up. Frontiers in Immunology, 2022, 13, 818325.	4.8	5
4	Docking Protein p130Cas Regulates Acinar to Ductal Metaplasia During Pancreatic Adenocarcinoma Development and Pancreatitis. Gastroenterology, 2022, 162, 1242-1255.e11.	1.3	4
5	Exploring chitosan-shelled nanobubbles to improve HER2 + immunotherapy via dendritic cell targeting. Drug Delivery and Translational Research, 2022, 12, 2007-2018.	5 . 8	8
6	IL17A critically shapes the transcriptional program of fibroblasts in pancreatic cancer and switches on their protumorigenic functions. Proceedings of the National Academy of Sciences of the United States of America, 2021 , 118 , .	7.1	27
7	The Glycolytic Pathway as a Target for Novel Onco-Immunology Therapies in Pancreatic Cancer. Molecules, 2021, 26, 1642.	3 . 8	9
8	IL17A Depletion Affects the Metabolism of Macrophages Treated with Gemcitabine. Antioxidants, 2021, 10, 422.	5.1	2
9	Low Levels of Urinary PSA Better Identify Prostate Cancer Patients. Cancers, 2021, 13, 3570.	3.7	9
10	Diabetes promotes invasive pancreatic cancer by increasing systemic and tumour carbonyl stress in KrasG12D/+ mice. Journal of Experimental and Clinical Cancer Research, 2020, 39, 152.	8.6	15
11	In pancreatic cancer, chemotherapy increases antitumor responses to tumor-associated antigens and potentiates DNA vaccination., 2020, 8, e001071.		24
12	Computational modeling of the immune response in multiple sclerosis using epimod framework. BMC Bioinformatics, 2020, 21, 550.	2.6	9
13	Metabolome of Pancreatic Juice Delineates Distinct Clinical Profiles of Pancreatic Cancer and Reveals a Link between Glucose Metabolism and PD-1+ Cells. Cancer Immunology Research, 2020, 8, 493-505.	3.4	26
14	Proteomics-Based Evidence for a Pro-Oncogenic Role of ESRP1 in Human Colorectal Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 575.	4.1	12
15	Immune-Complexome Analysis Identifies Immunoglobulin-Bound Biomarkers That Predict the Response to Chemotherapy of Pancreatic Cancer Patients. Cancers, 2020, 12, 746.	3.7	6
16	The dark side of immunotherapy: pancreatic cancer., 2020, 3, 491-520.		15
17	Integrative Analysis of Novel Metabolic Subtypes in Pancreatic Cancer Fosters New Prognostic Biomarkers. Frontiers in Oncology, 2019, 9, 115.	2.8	32
18	Stromal protein \hat{l}^2 ig-h3 reprogrammes tumour microenvironment in pancreatic cancer. Gut, 2019, 68, 693-707.	12.1	79

#	Article	IF	Citations
19	Phosphoinositide 3-Kinase Gamma Inhibition Protects From Anthracycline Cardiotoxicity and Reduces Tumor Growth. Circulation, 2018, 138, 696-711.	1.6	145
20	The advanced glycation endâ€product <i>N</i> ^ϵ â€carboxymethyllysine promotes progression of pancreatic cancer: implications for diabetesâ€associated risk and its prevention. Journal of Pathology, 2018, 245, 197-208.	4.5	43
21	Beta-2-glycoprotein-1 and alpha-1-antitrypsin as urinary markers of renal cancer in von Hippel–Lindau patients. Biomarkers, 2018, 23, 123-130.	1.9	12
22	Depletion of tumor-associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-tumor phenotype. Oncolmmunology, 2018, 7, e1393596.	4.6	58
23	FAM49B, a novel regulator of mitochondrial function and integrity that suppresses tumor metastasis. Oncogene, 2018, 37, 697-709.	5.9	49
24	Soluble stromaâ€related biomarkers of pancreaticÂcancer. EMBO Molecular Medicine, 2018, 10, .	6.9	56
25	Next Generation Immunotherapy for Pancreatic Cancer: DNA Vaccination is Seeking New Combo Partners. Cancers, 2018, 10, 51.	3.7	21
26	Pregnancy Epigenetic Signature in T Helper 17 and T Regulatory Cells in Multiple Sclerosis. Frontiers in Immunology, 2018, 9, 3075.	4.8	26
27	Adenosine A2a receptor stimulation blocks development of nonalcoholic steatohepatitis in mice by multilevel inhibition of signals that cause immunolipotoxicity. Translational Research, 2017, 182, 75-87.	5.0	23
28	Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis. Journal of Hematology and Oncology, 2017, 10, 16.	17.0	101
29	The ATP-binding cassette transporter A1 regulates phosphoantigen release and VÎ ³ 9VÎ 2 T cell activation by dendritic cells. Nature Communications, 2017, 8, 15663.	12.8	57
30	Regulation of Human Macrophage M1–M2 Polarization Balance by Hypoxia and the Triggering Receptor Expressed on Myeloid Cells-1. Frontiers in Immunology, 2017, 8, 1097.	4.8	208
31	Alpha-Enolase i ENO1 i a potential target in novel immunotherapies. Frontiers in Bioscience - Landmark, 2017, 22, 944-959.	3.0	68
32	Overcoming the lack of kinetic information in biochemical reactions networks. Performance Evaluation Review, 2017, 44, 91-102.	0.6	2
33	Next generation of cancer immunotherapy calls for combination. Oncoscience, 2017, 4, 19-20.	2.2	6
34	Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia. Oncotarget, 2017, 8, 3274-3288.	1.8	13
35	Endogenous glutamine decrease is associated with pancreatic cancer progression. Oncotarget, 2017, 8, 95361-95376.	1.8	41
36	Dealing with indetermination in biochemical networks. , 2017, , .		0

#	Article	IF	CITATIONS
37	Cancer and Chemotherapy Contribute to Muscle Loss by Activating Common Signaling Pathways. Frontiers in Physiology, 2016, 7, 472.	2.8	138
38	Protein disulfide isomerase A3–specific Th1 effector cells infiltrate colon cancer tissue of patients with circulating anti–protein disulfide isomerase A3 autoantibodies. Translational Research, 2016, 171, 17-28.e2.	5.0	27
39	Macrophage PI3K \hat{I}^3 Drives Pancreatic Ductal Adenocarcinoma Progression. Cancer Discovery, 2016, 6, 870-885.	9.4	235
40	Regulation of Langerhans cell functions in a hypoxic environment. Journal of Molecular Medicine, 2016, 94, 943-955.	3.9	10
41	The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice. Clinical Science, 2016, 130, 193-203.	4.3	116
42	Intra-tumoral IFN- \hat{l}^3 -producing Th22 cells correlate with TNM staging and the worst outcomes in pancreatic cancer. Clinical Science, 2016, 130, 247-258.	4.3	29
43	Peripheral ENO1-specific T cells mirror the intratumoral immune response and their presence is a potential prognostic factor for pancreatic adenocarcinoma. International Journal of Oncology, 2016, 49, 393-401.	3.3	23
44	Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma. Oncolmmunology, 2016, 5, e1085147.	4.6	169
45	Alemtuzumab long-term immunologic effect. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e194.	6.0	65
46	Anti-α-enolase antibody limits the invasion of myeloid-derived suppressor cells and attenuates their restraining effector T cell response. Oncolmmunology, 2016, 5, e1112940.	4.6	19
47	Targeting the Warburg effect in cancer cells through ENO1 knockdown rescues oxidative phosphorylation and induces growth arrest. Oncotarget, 2016, 7, 5598-5612.	1.8	118
48	ATP-Binding-Cassette A1 Regulates Extracellular Isopentenyl Pyrophosphate Release and VÎ ³ 9Vδ2 T-Cell Activation By Dendritic Cells. Blood, 2016, 128, 3709-3709.	1.4	0
49	Proteomic analysis of extracellular vesicles from medullospheres reveals a role for iron in the cancer progression of medulloblastoma. Molecular and Cellular Therapies, 2015, 3, 8.	0.2	19
50	Pharmacological Preconditioning by Adenosine A2a Receptor Stimulation: Features of the Protected Liver Cell Phenotype. BioMed Research International, 2015, 2015, 1-9.	1.9	11
51	Pancreatic cancer vaccine: a unique potential therapy. Gastrointestinal Cancer: Targets and Therapy, 2015, , 1.	5.5	0
52	Mouse hepatocytes and LSEC proteome reveal novel mechanisms of ischemia/reperfusion damage and protection by A2aR stimulation. Journal of Hepatology, 2015, 62, 573-580.	3.7	30
53	Phosphorylated alpha-enolase induces autoantibodies in HLA-DR8 pancreatic cancer patients and triggers HLA-DR8 restricted T-cell activation. Immunology Letters, 2015, 167, 11-16.	2.5	14
54	Oxidative stress-mediated antimalarial activity of plakortin, a natural endoperoxide from the tropical sponge Plakortis simplex. Free Radical Biology and Medicine, 2015, 89, 624-637.	2.9	21

#	Article	IF	CITATIONS
55	Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells. Oncotarget, 2015, 6, 11098-11113.	1.8	83
56	Class II Transactivator-Induced MHC Class II Expression in Pancreatic Cancer Cells Leads to Tumor Rejection and a Specific Antitumor Memory Response. Pancreas, 2014, 43, 1066-1072.	1.1	14
57	Chimeric Rat/Human HER2 Efficiently Circumvents HER2 Tolerance in Cancer Patients. Clinical Cancer Research, 2014, 20, 2910-2921.	7.0	24
58	Th22 cells are expanded in multiple sclerosis and are resistant to IFN- \hat{l}^2 . Journal of Leukocyte Biology, 2014, 96, 1155-1164.	3.3	71
59	Reduced cellular Ca2+ availability enhances TDP-43 cleavage by apoptotic caspases. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 725-734.	4.1	17
60	Natural-born killers unleashed. Nature, 2014, 510, 342-343.	27.8	7
61	Mass spectrometric analysis reveals O-methylation of pyruvate kinase from pancreatic cancer cells. Analytical and Bioanalytical Chemistry, 2013, 405, 4937-4943.	3.7	6
62	Chronic hypoxia reprograms human immature dendritic cells by inducing a proinflammatory phenotype and <scp>TREM</scp> â€l expression. European Journal of Immunology, 2013, 43, 949-966.	2.9	49
63	Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions. Cancer Immunology, Immunotherapy, 2013, 62, 1249-1260.	4.2	102
64	Vaccination With ENO1 DNA Prolongs Survival of Genetically Engineered Mice With Pancreatic Cancer. Gastroenterology, 2013, 144, 1098-1106.	1.3	104
65	Quartz crystal microbalance with dissipation (QCM-D) as tool to exploit antigen–antibody interactions in pancreatic ductal adenocarcinomadetection. Biosensors and Bioelectronics, 2013, 42, 646-652.	10.1	29
66	Early expression of the fractalkine receptor CX3CR1 in pancreatic carcinogenesis. British Journal of Cancer, 2013, 109, 2424-2433.	6.4	26
67	Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. Journal of Hematology and Oncology, 2013, 6, 67.	17.0	42
68	Three are better than one: plasminogen receptors as cancer theranostic targets. Experimental Hematology and Oncology, 2013, 2, 12.	5.0	33
69	Towards pancreatic cancer diagnosis using EIS biochips. Lab on A Chip, 2013, 13, 730.	6.0	32
70	A self antigen reopens the games in pancreatic cancer. Oncolmmunology, 2013, 2, e24384.	4.6	8
71	Acute-Phase Protein Hemopexin Is a Negative Regulator of Th17 Response and Experimental Autoimmune Encephalomyelitis Development. Journal of Immunology, 2013, 191, 5451-5459.	0.8	28
72	STAT1 and STAT3 in tumorigenesis. Jak-stat, 2012, 1, 65-72.	2.2	193

#	Article	IF	Citations
73	Th17 Cells in Multiple Sclerosis Express Higher Levels of JAK2, Which Increases Their Surface Expression of IFN- \hat{I}^3 R2. Journal of Immunology, 2012, 188, 1011-1018.	0.8	26
74	Molecular and Genetic Bases of Pancreatic Cancer. Current Drug Targets, 2012, 13, 731-743.	2.1	24
75	Proteomic Analysis Reveals Warburg Effect and Anomalous Metabolism of Glutamine in Pancreatic Cancer Cells. Journal of Proteome Research, 2012, 11, 554-563.	3.7	81
76	MS analysis reveals <scp>O</scp> â€methylation of <i><scp>L</scp></i> à€lactate dehydrogenase from pancreatic ductal adenocarcinoma cells. Electrophoresis, 2012, 33, 1850-1854.	2.4	11
77	Proteomic Analysis of Pancreatic Ductal Adenocarcinoma Cells Reveals Metabolic Alterations. Journal of Proteome Research, 2011, 10, 1944-1952.	3.7	46
78	Circulating Autoantibodies to Phosphorylated \hat{l}_{\pm} -Enolase are a Hallmark of Pancreatic Cancer. Journal of Proteome Research, 2011, 10, 105-112.	3.7	119
79	Hypoxia modulates the gene expression profile of immunoregulatory receptors in human mature dendritic cells: identification of TREM-1 as a novel hypoxic marker in vitro and in vivo. Blood, 2011, 117, 2625-2639.	1.4	119
80	αâ€enolase: a promising therapeutic and diagnostic tumor target. FEBS Journal, 2011, 278, 1064-1074.	4.7	209
81	Investigation of the Ovarian and Prostate Cancer Peptidome for Candidate Early Detection Markers Using a Novel Nanoparticle Biomarker Capture Technology. AAPS Journal, 2010, 12, 504-518.	4.4	51
82	Expression of IFN \hat{I}^3 R2 mutated in a dileucine internalization motif reinstates IFN \hat{I}^3 signaling and apoptosis in human T lymphocytes. Immunology Letters, 2010, 134, 17-25.	2.5	12
83	Mass Spectrometry Analysis of the Post-Translational Modifications of α-Enolase from Pancreatic Ductal Adenocarcinoma Cells. Journal of Proteome Research, 2010, 9, 2929-2936.	3.7	66
84	Tâ€helper 17 cells expand in multiple sclerosis and are inhibited by interferonâ€Î². Annals of Neurology, 2009, 65, 499-509.	5.3	340
85	An integrated humoral and cellular response is elicited in pancreatic cancer by αâ€enolase, a novel pancreatic ductal adenocarcinomaâ€associated antigen. International Journal of Cancer, 2009, 125, 639-648.	5.1	115
86	IL-6, but not IFN- \hat{I}^3 , triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing. Leukemia, 2009, 23, 2102-2108.	7.2	31
87	Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: engraftment and hepatocyte differentiation versus profibrogenic potential. Gut, 2008, 57, 223-231.	12.1	248
88	Ups and downs: The STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling. Seminars in Cell and Developmental Biology, 2008, 19, 351-359.	5.0	206
89	Human dendritic cells differentiated in hypoxia down-modulate antigen uptake and change their chemokine expression profile. Journal of Leukocyte Biology, 2008, 84, 1472-1482.	3.3	88
90	CCL16 Enhances the CD8+ and CD4+ T Cell Reactivity to Human Her-2 Elicited by Dendritic Cells Loaded with Rat Ortholog Her-2. International Journal of Immunopathology and Pharmacology, 2008, 21, 867-877.	2.1	6

#	Article	IF	Citations
91	Type I IFN inhibits the expansion of Th17 lymphocytes from both healthy subjects and Multiple Sclerosis patients. FASEB Journal, 2008, 22, 1069.6.	0.5	1
92	In the absence of IGF-1 signaling, IFN- \hat{l}^3 suppresses human malignant T-cell growth. Blood, 2007, 109, 2496-2504.	1.4	20
93	IFN-γ regulates Fas ligand expression in human CD4+ T lymphocytes and controls their anti-mycobacterial cytotoxic functions. European Journal of Immunology, 2007, 37, 2196-2204.	2.9	26
94	Autoantibody Signature in Human Ductal Pancreatic Adenocarcinoma. Journal of Proteome Research, 2007, 6, 4025-4031.	3.7	88
95	The NEMO Mutation Creating the Most-Upstream Premature Stop Codon Is Hypomorphic Because of a Reinitiation of Translation. American Journal of Human Genetics, 2006, 78, 691-701.	6.2	89
96	IFNγR2 trafficking tunes IFNγ–STAT1 signaling in T lymphocytes. Trends in Immunology, 2006, 27, 96-101.	6.8	46
97	CC-Chemokine Ligand 16 Induces a Novel Maturation Program in Human Immature Monocyte-Derived Dendritic Cells. Journal of Immunology, 2006, 177, 6143-6151.	0.8	21
98	Iron regulates T-lymphocyte sensitivity to the IFN- $\hat{l}^3/STAT1$ signaling pathway in vitro and in vivo. Blood, 2005, 105, 3214-3221.	1.4	40
99	IFN- \hat{l}^3 inhibits the proliferation of allergen-activated T lymphocytes from atopic, asthmatic patients by inducing Fas/FasL-mediated apoptosis. Journal of Leukocyte Biology, 2004, 76, 423-432.	3.3	37
100	Retroviral-mediated gene transfer restores IL-12 and IL-23 signaling pathways in T cells from IL-12 receptor \hat{l}^2 1-deficient patients. Molecular Therapy, 2004, 9, 895-901.	8.2	11
101	CCL16/LEC powerfully triggers effector and antigen-presenting functions of macrophages and enhances T cell cytotoxicity. Journal of Leukocyte Biology, 2004, 75, 135-142.	3.3	37
102	The role of IL-12, IL-23 and IFN- \hat{l}^3 in immunity to viruses. Cytokine and Growth Factor Reviews, 2004, 15, 367-377.	7.2	95
103	IGF-1 down-regulates IFN-Î ³ R2 chain surface expression and desensitizes IFN-Î ³ /STAT-1 signaling in human T lymphocytes. Blood, 2003, 102, 2933-2939.	1.4	45
104	Requirement for both IL-12 and IFN- \hat{I}^3 signaling pathways in optimal IFN- \hat{I}^3 production by human T cells. European Journal of Immunology, 2002, 32, 693.	2.9	23
105	IFN-gamma and IL-12 differentially regulate CC-chemokine secretion and CCR5 expression in human T lymphocytes. Journal of Leukocyte Biology, 2002, 72, 735-42.	3.3	14
106	Biased activation of human T lymphocytes due to low extracellular pH is antagonized by B7/CD28 costimulation. European Journal of Immunology, 2001, 31, 2829-2838.	2.9	59
107	Regulation of interferon-gamma receptor (INF-gammaR) chains: a peculiar way to rule the life and death of human lymphocytes. European Cytokine Network, 2001, 12, 6-14.	2.0	24
108	Interferon-gamma receptor 2 expression as the deciding factor in human T, B, and myeloid cell proliferation or death. Journal of Leukocyte Biology, 2001, 70, 950-60.	3.3	93

#	Article	IF	Citations
109	Surface Expression of the IFN-13R2 Chain Is Regulated by Intracellular Trafficking in Human T Lymphocytes. Journal of Immunology, 2000, 164, 201-207.	0.8	44
110	Partial Interferonâ€Î³ Receptor Signaling Chain Deficiency in a Patient with Bacille Calmetteâ€Guérin andMycobacterium abscessusInfection. Journal of Infectious Diseases, 2000, 181, 379-384.	4.0	171
111	Inheritable defects in interleukinâ€12―and interferonâ€gammaâ€mediated immunity and the TH1/TH2 paradigm in man. Allergy: European Journal of Allergy and Clinical Immunology, 1999, 54, 409-412.	5.7	31
112	Expression and Role of IL-15 in Post-Burn Hypertrophic Scars. Journal of Investigative Dermatology, 1999, 113, 238-245.	0.7	28
113	Functional analysis of T lymphocytes infiltrating the dermis and epidermis of post-burn hypertrophic scar tissues. Burns, 1999, 25, 43-48.	1.9	23
114	Nitric oxide suppresses human T lymphocyte proliferation through IFN-gamma-dependent and IFN-gamma-independent induction of apoptosis. Journal of Immunology, 1999, 163, 4182-91.	0.8	69
115	Beta-galactoside-binding protein (beta GBP) alters the cell cycle, up-regulates expression of the alpha- and beta-chains of the IFN-gamma receptor, and triggers IFN-gamma-mediated apoptosis of activated human T lymphocytes. Journal of Immunology, 1998, 161, 2114-9.	0.8	46
116	Antiblastic chemotherapy drugs up-modulate interferon-gamma receptor expression on human malignant T cells. Cancer Detection and Prevention, 1997, 21, 191-5.	2.1	1
117	Expression and role in apoptosis of the alpha- and beta-chains of the IFN-gamma receptor on human Th1 and Th2 clones. Journal of Immunology, 1997, 159, 206-13.	0.8	49
118	Switching on of the proliferation or apoptosis of activated human T lymphocytes by IFN-gamma is correlated with the differential expression of the alpha- and beta-chains of its receptor. Journal of Immunology, 1996, 157, 1935-43.	0.8	72
119	Environmental signals influencing expression of the IFN-gamma receptor on human T cells control whether IFN-gamma promotes proliferation or apoptosis. Journal of Immunology, 1994, 152, 496-504.	0.8	58
120	Modulation of interferon- \hat{l}^3 receptor during human T lymphocyte alloactivation. European Journal of Immunology, 1993, 23, 1226-1231.	2.9	14
121	Distribution of interferon- \hat{l}^3 receptor in human tissues. European Journal of Immunology, 1992, 22, 2403-2412.	2.9	165
122	Blockade of physiologically secreted IFN-gamma inhibits human T lymphocyte and natural killer cell activation. Journal of Immunology, 1991, 147, 1445-52.	0.8	33
123	Single kidney function: Effect of acute protein and water loading on microalbuminuria. American Journal of Medicine, 1988, 84, 711-717.	1.5	15
124	Definition by CB12 monoclonal antibody of a differentiation marker specific for human monocytes and their bone marrow precursors. Cellular Immunology, 1986, 97, 276-285.	3.0	9